SCHEMBL21464697

SCHEMBL21464697

CC(C)(C)N(CCNc1ncc(B2OC(C)(C)C(C)(C)O2)cn1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.42
FFAR1 O14842 1/20 0.38
ROCK2 O75116 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
USP30 Q70CQ3 2/20 0.34
AAK1 Q2M2I8 2/20 0.32
CXCR2 P25025 1/20 0.32
HIF1A Q16665 1/20 0.31
F2 P00734 2/20 0.31
F11 P03951 2/20 0.31
PRSS1 P07477 2/20 0.31
PRSS2 P07478 2/20 0.31
PRSS3 P35030 2/20 0.31
PRMT5 O14744 1/20 0.30
WDR77 Q9BQA1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1283942 0.80 DGAT1 (0.44) DGAT1FFAR1GSK3AGSK3BPDGFRB
SCHEMBL18991898 0.78 DGAT1 (0.41) DGAT1FFAR1ROCK2GSK3AGSK3B
SCHEMBL20480489 0.76 HIF1A (0.40) DGAT1PDGFRBKDRAAK1HIF1A
SCHEMBL31217159 0.76 FFAR1 (0.35) DGAT1FFAR1GSK3AGSK3B
SCHEMBL1841804 0.76 DGAT1 (0.43) DGAT1FFAR1ROCK2GSK3AGSK3B
SCHEMBL19949163 0.76 FFAR1 (0.41) DGAT1FFAR1ROCK2GSK3AGSK3B
SCHEMBL22715892 0.75 FFAR1 (0.56) DGAT1FFAR1USP30F2F11
SCHEMBL21464703 0.74 PRMT5 (0.46) DGAT1FFAR1ROCK2USP30AAK1
SCHEMBL29891611 0.73 STK17B (0.48) DGAT1USP30AAK1PRMT5WDR77
SCHEMBL3412319 0.73 CA1 (0.43) F2F11PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637450-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways GLOBAL CANCER TECHNOLOGY INC. (US) 2026-05-26 US disclosed
EP-3774783-B1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES INC (US) 2025-06-04 EP disclosed
US-20240327396-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES, INC. (US) 2024-10-03 US disclosed
US-12049462-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways NEUROPORE THERAPIES, INC. (US) 2024-07-30 US disclosed
US-20230265086-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES, INC. (US) 2023-08-24 US disclosed
US-11492348-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways NEUROPORE THERAPIES, INC. (US) 2022-11-08 US disclosed
US-20210163462-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES, INC. (US) 2021-06-03 US disclosed
EP-3774783-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS Neuropore Therapies, Inc. (US) 2021-02-17 EP disclosed
WO-2019199864-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES, INC. (US) 2019-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11492348-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways ATG7, ULK1, BECN1 DGAT1 1349/4885FFAR1 2140/4885ROCK2 740/4885
US-20210163462-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS ATG7, ULK1, BECN1 DGAT1 1349/4885FFAR1 2140/4885ROCK2 740/4885
US-12637450-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways PIK3R4, PIK3R1, ATG7 DGAT1 1496/4885FFAR1 534/4885ROCK2 1118/4885
US-20240327396-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS ATG7, ULK1, BECN1 DGAT1 1349/4885FFAR1 2140/4885ROCK2 740/4885
US-12049462-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways ATG7, ULK1, BECN1 DGAT1 1314/4885FFAR1 2093/4885ROCK2 736/4885
US-20230265086-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS ATG7, ULK1, BECN1 DGAT1 1349/4885FFAR1 2140/4885ROCK2 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.